Before you stop your statin — read this

YOUR HEALTH — Issue No. 14

Every week I have the same conversation.

A patient comes in. Their LDL is elevated. Their 10-year cardiovascular risk is meaningful. The data is clear. And they look at me and say — I don't want to take a statin.

I understand why. High cholesterol doesn't feel like anything. You cannot feel plaque building in your arteries the way you feel a headache or a swollen knee. High blood pressure at least carries a warning — people connect it to stroke, to the pressure they feel, to something tangible. Cholesterol is invisible. And invisible threats are easy to dismiss.

But here is what I tell my patients: the mechanism that causes most heart attacks and strokes is not simply a number on a lab report. It is plaque — built up over years on artery walls from excess LDL cholesterol depositing beneath the vessel lining — that becomes unstable, ruptures, and sends a clot to the heart or brain. That clot is what kills you. And the single most effective medication we have for slowing that process, stabilizing that plaque, and reducing the risk of that event is a statin.

So how did we get here? How did one of the most studied medication classes in the history of medicine become one of the most refused?

The answer involves fear, misinformation, and a genuine clinical conversation that too often doesn't happen in the exam room. This issue is that conversation.

Why statins matter — the data behind the push

Cardiovascular disease kills more Americans than all cancers combined. It is responsible for more than one in four deaths in the United States every year. That is not a statistic providers use to frighten patients — it is the clinical reality that drives every conversation about cholesterol management.

Statins have been studied in thousands of randomized controlled trials involving millions of patients across decades. No medication class in medicine has more evidence behind it. The data is not ambiguous.

For every meaningful reduction in LDL cholesterol, cardiovascular event risk drops approximately 20-25%. Stroke risk falls by approximately 21-22%. These are not marginal benefits — they represent real lives, real events, and real outcomes prevented.

But statins do something beyond lowering a number on a lab report — and this is the part most patients never hear.

Plaque stabilization — the mechanism that matters most:

Statins do not simply reduce LDL cholesterol in the bloodstream. At higher intensities, they change the physical composition of existing plaques inside artery walls. Clinical trials using intravascular imaging have shown that statins reduce the lipid-rich, unstable core of plaques — the part most likely to rupture — while increasing the fibrous cap that keeps plaques stable.

In plain terms: a statin does not just slow new plaque from forming. It makes existing plaque less dangerous. A stable plaque stays in place. An unstable plaque ruptures — and that rupture is what triggers a heart attack or stroke.

This is why providers push statins. Not because of a number on a lab report. Because of what happens when that plaque becomes unstable.

What high intensity actually means

When a provider prescribes a statin, the dose matters as much as the medication. The ACC/AHA guidelines divide statin therapy into three intensity levels:

High intensity — atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily. Goal: reduce LDL cholesterol by 50% or more.

Moderate intensity — atorvastatin 10-20 mg, rosuvastatin 5-10 mg, or simvastatin 20-40 mg daily. Goal: reduce LDL by 30-49%.

Low intensity — lower doses of older statins. Less commonly used in current practice.

High intensity therapy is recommended for patients with established cardiovascular disease — prior heart attack, stroke, or peripheral artery disease — and for patients under 75 with a 10-year ASCVD risk above 20%. For patients over 75 with established disease, moderate intensity therapy is generally preferred.

The goal is not simply to get LDL below a specific number — it is to achieve a meaningful percentage reduction from baseline. That percentage reduction is what drives the clinical benefit.

The fear — and where it comes from

Ask a patient why they don't want a statin and you will hear a version of the same answer: someone they know had muscle pain, or liver damage, or memory problems. Someone told them statins are poison. They read something online. They saw something on social media.

This is the reality of prescribing in 2026. Patients arrive in the exam room already influenced — by influencers, by testimonials, by fear-based content that spreads faster than clinical evidence.

Here is what the evidence actually shows.

Muscle symptoms — the most common concern

Muscle pain is the most frequently cited reason patients stop their statin. And the fear is understandable — if a medication is causing pain, stopping it seems like common sense.

But a landmark analysis published in The Lancet — examining over 150,000 patients across 23 blinded clinical trials — found that most muscle symptoms reported during statin therapy also occurred during placebo treatment and could not be attributed to the drug. The nocebo effect — experiencing symptoms because you expect to — is real and measurable, and it accounts for the majority of reported statin-related muscle complaints.

Genuine statin-related myopathy does exist. It is rare — approximately one case per 10,000 patient-years — and occurs more commonly at higher doses and in patients on certain interacting medications. Rhabdomyolysis — the severe form of muscle breakdown — is extremely rare.

One important clinical pearl: In trials where patients who stopped statins for muscle pain underwent a washout period and were then rechallenged with either a statin or placebo under blinded conditions — 30-40% had no muscle symptoms on rechallenge. This means a meaningful proportion of patients who believe they cannot tolerate a statin actually can, when the expectation of side effects is removed.

If you stopped a statin because of muscle pain — this conversation is worth having with your provider before assuming that medication is off the table permanently.

Liver damage — what the data shows

Liver damage is one of the most commonly cited statin fears — and one of the most overstated.

Mild transaminase elevations — liver enzyme increases on lab work — can occur with statin use. They are generally dose-dependent, usually asymptomatic, and often resolve without stopping the medication. Serious hepatotoxicity from statins is extremely rare. The FDA removed the requirement for routine liver enzyme monitoring in statin users in 2012 — because the data did not support it as a meaningful safety concern in most patients.

Patients with pre-existing liver disease require more careful management — but for the majority of patients, the liver concern attached to statin therapy is not supported by the clinical evidence.

Memory loss — what the data actually shows

Memory loss and cognitive complaints are among the most frequently cited reasons patients refuse or stop statin therapy. In 2012, the FDA added a warning to statin labels noting rare reports of memory loss and confusion — which understandably alarmed patients.

What the label also states — and what rarely gets communicated — is that these cognitive effects were generally not serious, non-progressive, and reversed when the medication was stopped.

More striking: large-scale research consistently finds that long-term statin use is associated with a lower risk of dementia — not a higher one. A 2025 analysis of over 7 million patients found statin users had significantly lower dementia risk. The medication millions of patients stopped because they feared it would harm their memory may actually be doing the opposite.

The dementia data is observational — association, not proven causation. But it points in a direction that is the opposite of the fear.

New-onset diabetes — the one real signal

This is the side effect that deserves honest acknowledgment — because it is real.

Statin therapy is associated with a small but measurable increase in the risk of developing Type 2 diabetes. But here is the clinical nuance that most patients never hear: the risk is almost entirely concentrated in patients who were already close to the diagnostic threshold for diabetes. Patients with pre-diabetes, high triglycerides, or elevated BMI carry a significantly higher risk. Patients with normal fasting glucose and no metabolic risk factors have an incidence of only 2-3%.

What this tells us clinically: the statin did not cause diabetes out of nowhere. It tipped the scale in a patient who was already standing at the edge.

If you have pre-diabetes or metabolic risk factors and are starting a statin — lifestyle modification is not optional. The same diet, exercise, and weight management that protects your cardiovascular system also reduces your risk of statin-associated diabetes.

And here is the part worth sitting with: if a statin pushes a patient into a diabetes diagnosis, that patient's cardiovascular risk just went up. Which makes the statin more important — not less.

Primary versus secondary prevention — the distinction that matters most

Not all statin recommendations are the same. The most important distinction in statin therapy is whether you are being treated for primary or secondary prevention.

Secondary prevention — you have already had a heart attack, stroke, or have established cardiovascular disease. The evidence for statin therapy in secondary prevention is among the strongest in medicine, at any age. If you are in this category and are not on a statin — that conversation needs to happen.

Primary prevention — you have never had a cardiovascular event. Here the decision is more nuanced and depends on your individual risk profile. For adults between 40 and 75 with a 10-year ASCVD risk above 7.5-10%, statin therapy is generally recommended. For lower risk individuals, the absolute benefit is smaller and the decision should be individualized.

Adults over 75 — an important nuance:
For adults over 75 who have never had a cardiovascular event, the evidence for starting a statin specifically for primary prevention is less certain. The USPSTF has issued an insufficient evidence statement for this population — meaning the data does not clearly support or oppose it. Starting a statin in a healthy 78-year-old with no prior cardiovascular events is a different clinical decision than continuing a statin in a 78-year-old who had a heart attack at 65.

If you are over 75 and on a statin — this does not mean you should stop it. It means the conversation about why you are on it and what category of prevention it represents is worth having with your provider.

The adherence problem

Nearly half of all patients prescribed a statin stop taking it within the first year. Most stop because of perceived side effects — side effects that, as we have discussed, are frequently attributable to the nocebo effect rather than the medication itself.

The clinical consequence of stopping is real. Discontinuation of statin therapy is consistently associated with increased cardiovascular events, hospitalizations, and all-cause mortality. The medication works when taken. The problem is human behavior — not the drug.

If you are considering stopping your statin — please have that conversation with your provider first. Do not make that decision based on something you read online or heard from a friend.

Something worth saying plainly:

Not every patient who needs a statin can take one. True statin intolerance is real — and for those patients, alternative lipid-lowering therapies exist. But confirmed intolerance is far less common than the number of patients who have stopped their statin would suggest.

Cardiovascular disease does not always announce itself. You can have a perfect LDL and still have a heart attack. You can do everything your provider asks and still have a stroke. That is the honest truth about cardiovascular risk — it is never zero.

But it is also reducible. The data on statins is among the strongest in medicine. For the patients who need them and can tolerate them — they work. Control what you can control.

The Member deep-dive this week covers PCSK9 inhibitors and what the data actually shows about statin alternatives, ezetimibe (Zetia) — the overlooked oral option with real outcomes data, CoQ10 and statin-associated muscle symptoms, and what to do if you have stopped a statin and aren't sure whether to try again.

Next week: ASCVD Risk — your 10-year heart risk number, what it means, and the free Plain Medicine calculator that lets you calculate it yourself.

Plain Medicine is published for educational purposes only and does not constitute medical advice or establish a patient-provider relationship. Always consult your healthcare provider before making medical decisions.

— Kyle